Journal Logo



In'T Hout, F.1; Gerritsen, M.2; Bullinger, L.3; van der Reijden, B.1; Huls, G.2; Vellenga, E.2; Jansen, J.1

doi: 10.1097/01.HS9.0000562280.87064.14
Poster Session II: Acute myeloid leukemia - Biology & translational research

1deparment of laboratory medicine - laboratory of hematology, RadboudUMC, Nijmegen

2Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, Groningen, Netherlands

3Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine, Berlin, Germany

Back to Top | Article Outline


Aberrations of the RUNX1 transcription factor, either mutations (RUNX1mut) or translocations t(8;21) creating a RUNX1-RUNXT1 fusion gene, are frequently observed in AML. However, the pathomechanisms underlying RUNX1mut AML and explaining its poor prognosis in contrast to t(8;21) cases are still poorly understood.

Back to Top | Article Outline


As recent data suggested deregulation of the transcription factor 4 (TCF4) gene to play a potential role, we studied the importance of TCF4 in the context of RUNX1mut and t(8;21).

Back to Top | Article Outline


Chip-sequencing data was analyzed to identify binding of RUNX1 on the TCF4 promoter and Luciferarse reporter assays were used to assay impact of RUNX1 on TCF4 promoter activity.

CD34+ UCB cells were transduced with a pRRL construct overexpressing the RUNX1 R201Q mutant (RUNX1mut) or an empty vector (EV). Simultaneously, TCF4-RNAi (TCF4kd) or a non-targeting control (NT) was co-transduced. These double transduced CD34+ UCB cells were cultured on MS5 bone marrow stromal layer and proliferation assays, colony forming unit assays and long-term culture-initiating cells assays were performed. TCF4 expression values were derived from a previously reported cohort of 436 AML patients of which 330 had a known RUNX1 status. Survival curves were calculated by the Kaplan-Meier method and compared using the logrank test. Multivariate survival analysis was carried out using the Cox proportional hazards model, and covariates included were RUNX1 mutation and white blood cell count (WBC > 100 *109/L) with and without TCF4 expression (lowest 75% vs highest 25%).

Back to Top | Article Outline


While TCF4 is found upregulated in RUNX1mut in contrast to t(8;21) AML, Chip-seq and transactivation assays revealed that RUNX1 binds and regulates the TCF4 promoter activity. RUNX1 wild type (RUNX1wt) and the RUNX1-RUNX1T1 fusion protein repressed TCF4 promoter activity, which was lost in RUNX1mut AML. In CD34+ cells RUNX1mut enhanced colony-formation and increased long-term culture initiating cells, whereas RNA interference based TCF4 downregulation in RUNX1mut cells abolished this effect. Being required for stem cell maintenance activity in RUNX1mut AML, TCF4 upregulation accounted for the poor prognostic outcome of RUNX1mut in AML patients, as RUNX1mut lost its significance in multivariate analysis if TCF4 expression was included.

Back to Top | Article Outline


In summary, TCF4 is an important downstream target of RUNX1mut AML contributing to leukemogenesis and poor response to standard AML therapy.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.